Switching to a new GLP-1 means starting at the lowest dose

Heres a simplified breakdown for clinical practice Definition Sudden renal function Serum creatinine & blood urea Often urine output (oliguria) Classification of AKI Pre-Renal (Most Common) Renal perfusion Hypovolemia (dehydration, bleeding) Heart failure Drugs (NSAIDs, ACE inhibitors) Intrinsic (Renal) Kidney tissue damage Acute tubular necrosis (ATN) Glomerulonephritis Interstitial nephritis Post-Renal Obstruction to urine flow Stones Tumors Prostatic enlargement Pathophysiology (Simplified) Renal blood flow GFR Waste accumulation Fluid overload + Electrolyte imbalance Clinical Features Oliguria / Anuria Nausea, vomiting Fatigue Altered sensorium Fluid overload Edema, pulmonary edema Phases of AKI (ATN) 1 Oliguric Phase Low urine, hyperkalemia, overload 2 Maintenance Phase Low GFR, abnormal labs 3 Diuretic Phase Polyuria, dehydration risk Key Investigations Creatinine & urea Electrolytes Hyperkalemia, acidosis Urine casts help identify cause Ultrasound / Doppler if needed Management Priorities Treat underlying cause Optimize fluid balance (IV fluids / diuretics) Correct electrolytes & acidosis Avoid nephrotoxic drugs Dialysis Indications (Emergency) Refractory hyperkalemia Severe metabolic acidosis Pulmonary edema Uremic complications (encephalopathy, pericarditis) Nursing Insight: Close monitoring of urine output, creatinine trends, and electrolytes is crucial

This framework is outdated for people who want to protect their metabolic health rather than wait for it to deteriorate
The candid truth is that pharma hates the [managers] too because they cost the drug companies money, he told Healthline